RIFIVAS-400
RIFIVAS-400 contains Rifaximin 400 mg and is formulated as an oral tablet dosage form. Rifaximin is a semisynthetic rifamycin-class antibacterial compound characterized by limited systemic absorption and predominantly localized activity within the gastrointestinal tract. The active pharmaceutical ingredient is incorporated into a solid oral formulation designed to provide a consistent 400 mg strength per tablet. RIFIVAS-400 belongs to the antibiotic segment of the Suprimeda pharmaceutical portfolio and is presented as a conventional tablet formulation for pharmaceutical distribution. Rifaximin is recognized for its low systemic bioavailability, with pharmaceutical references describing its action as primarily localized within the gastrointestinal tract.
Everything You, Need to Know
RIFIVAS-400 is presented in a blister-pack format, with the product packaging shown as 10 × 10 tablets.
RIFIVAS-400 is available as an oral tablet formulation, containing 400 mg of Rifaximin per tablet.
RIFIVAS-400 contains Rifaximin 400 mg and is formulated as a tablet dosage form.